** Shares of drugmaker Biogen BIIB.O rise 2.8% to $118.42
** BIIB says that the final process for the European Commission's decision on the marketing authorization application for the company's Alzheimer's drug lecanemab is underway
** The update comes after the reconfirmation of the positive opinion for the drug's approval by the Committee for Medicinal Products for Human Use $(CHMP)$ in February 2025
** The therapy, already approved in U.S. and many other countries, could become Europe's first drug approved to treat the neurodegenerative condition directly rather than just its symptoms
** As of last close, stock has fallen 23.1% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。